Article date: May 2010
Patient information leaflets (PILs) are improving in quality as a result of new legal obligations on manufacturers to test the documents with potential patients. Testing makes sure that the presentation of the information enables patients to find and understand key messages for supporting safer use of the medicine within the PIL and thereby enables them to use the medicine safely and effectively. To promote this new initiative, we are publishing a series of examples of best practice on our website.
The latest example in the series is the leaflet for Durogesic D Trans Transdermal Patch, which contains fentanyl—a potent opioid analgesic used in the management of chronic intractable pain. The leaflet has recently been redesigned to clarify the posology for these patches and uses good navigation tools. In testing the leaflet was well received by patients.
Access PIL of the month via our website.
For further information to support safer use of fentanyl patches, see Drug Safety Update September 2008.
Article citation: Drug Safety Update May 2010, vol 3 issue 10: 9.